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reatment works.A generation of research has
led to this inescapable conclusion.A vast body of liter-
ature including complete textbooks, chapters, and
aggressive public and professional education campaigns
fully explicate this positive message.
1-3 Yet, among our-
selves,we are generally less positive about the impact of
our treatments on our patients’ lives.We will agree that
most patients do pretty well most of the time on most
treatments.But we will also agree that this is not nearly
good enough and much more needs to be learned about
how treatments work.
What, in particular, don’t we know as well as we would
like? Why do treatments rarely work as well in practice
as they do in clinical trials? Why are the approaches to
treatment that are studied in research settings rarely the
ones that are used in practice? Does treatment enhance
functioning? Does early treatment predict a more favor-
able response? How can we keep people well once they
have been made well? What approaches should be used
for the treatment-resistant patient?
These are the sorts of questions that are raised within
the context of what has been called a public health
model of treatment.
4These are questions we cannot yet
answer as well as we would like, however, largely
because the direction and culture of treatment research
has been determined by a more narrowly defined regu-
latory model.
5This regulatory model has been the dom-
inant force shaping treatment research in the past and
we will explore some of its limitations below.
Traditional (regulatory) clinical trials:
strengths and weaknesses
Most treatment studies are done with a very specific pur-
pose in mind:to gain approval or acceptance of a particu-
lar therapeutic modality.These studies are usually referred
The mental health field is transforming the culture of treatment research by moving from a narrow regulatory model geared
to drug approval and registration to a more inclusive public health model. Thus, whereas regulatory antidementia trials will
exclude patients with psychiatric or neurologic symptoms or substance abuse and require them to be physically healthy and
living with a caregiver, ie, 90% of the presenting Alzheimer population, the public health model promises to improve patient
care by addressing the types of practical questions and functional outcomes typically the concern of clinicians: Does treat-
ment enhance function? How can we keep people well once they have been made well? Why do treatments not work as
well in practice as in clinical trials? Public health studies are conducted in the world of actual practice with time-pressured
clinicians taking care of large numbers of patients with uncertain clinical presentations, complex comorbidities, and vary-
ing degrees of interference with ideal levels of compliance. The exclusive focus on symptoms is expanded to include out-
comes related to issues of function, disability, morbidity, mortality, resource use, and quality of life. Highly controlled effi-
cacy research is still needed to establish treatment merit, but efficacy now marks only the beginning of the process of inquiry.
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is appropriately referred to as a “regulatory”one.
Research following the regulatory model is specifically
geared to the legal requirements of drug approval and reg-
istration.Although there is no equivalent to the Food and
Drug Administration (FDA) for psychotherapy, the
methodology of the regulatory model has been adopted in
that field as well. In order to establish efficacy, it is essen-
tial that pure disease entities are isolated.This has led to
the practice of eliminating from clinical trials all patients
with comorbid illnesses, coexisting conditions, and even
potentially compromising psychosocial or environmental
characteristics. Dimensions of outcome are limited to the
direct symptomatic measures of that disease.Observation
periods are,typically,very short.In order to prevent admin-
istrative or delivery problems from masking the effect of
the treatment,clinicians are carefully selected and trained.
Intrusions such as the administrative requirements of a
health care plan or third party payer are minimized, and
the treatment is provided in optimal form,often in an aca-
demic health center.Specific measures are taken to ensure
compliance of the clinician with the protocol and adher-
ence of the patient with the procedures and treatments.
Formally, efficacy studies define optimal treatment out-
comes for narrowly selected patients treated under rigidly
controlled and ideal conditions.With a primary focus on
symptoms, the assessment of efficacy is based upon the
degree to which the level of symptomatology is reduced or
eliminated.
6,7 In an efficacy trial, treatment is provided by
specially selected and trained clinicians who provide opti-
mal treatment and expend substantial resources to ensure
compliance and minimize drop out.
Research supported for commercial purposes,particularly
that supported by the drug companies themselves, has, of
necessity, conformed to the regulatory model.This is the
case regardless of whether the site of the study is an acad-
emic health center or a community treatment facility,and
regardless of whether the coordination of the study is done
directly by the sponsor or by an intermediary (contract
research organization, or CRO). It is worth noting that
those doing clinical psychotherapeutic or behavioral
research have not (yet) adopted this CRO type of arrange-
ment.The regulatory model has also been carried over into
research that has no industrial sponsorship, even to
research on mental disorders that has been directed to gov-
ernment agencies or foundations.
In a treatment study driven by a regulatory model of inves-
tigation,there is no minimum effect size or minimum pro-
portion of responders necessary. In addition, there is no
requirement that the subject population be representative
of the kind of patient seen in actual practice.As such,a trial
done in accordance with the regulatory model represents
only the beginning of a process of clinical development.
Efficacy studies define optimal treatment outcomes for
narrowly selected patients treated under rigidly controlled
and ideal conditions.The classic efficacy trial is used to
define the gold standard of the best outcome under ideal
circumstances. Because of the tight standard of control
required in efficacy studies, the policy and practice rele-
vance of these trials will always be limited.
8
The clinical trials of cognitive enhancers provide a useful
example of the differences between regulatory and public
health research.The trials of cognitive enhancers seek to
show slowing or reversal of the progression of Alzheimer’s
disease or to demonstrate improved management of the
symptoms of the disease.These trials typically attempt to
show that the course of a progressive disease has been
modified.The design of such trials involves great complex-
ities even under optimal conditions.
9In an effort to demon-
strate efficacy within the regulatory model,current clinical
trials involving antidementia compounds typically exclude
any patient with psychiatric or neurologic symptoms or
substance abuse, and require the patient to be generally
physically healthy and living with a caregiver.Schneider et
al
10 applied these criteria to a large,state-wide database in
California and excluded all but 10% of patients.The result-
ing sample was younger,less severely ill,more highly edu-
cated,and more likely to be white and with higher incomes
than the population as a whole.These sorts of data provide
little guidance to the patient, family, or clinician in the
selection of treatment approaches.
In fact, there is a small but growing literature on issues
relating to subject selection in clinical trials.
11 In schizo-
phrenia,for example,subjects tend to be younger than the
general clinical population and are more likely to be male
and part of an ethnic minority.
12 In the Treatment Strate-
gies in Schizophrenia (TSS) study,fewer than 10% of those
screened were actually enrolled in the study.
12The story is
much the same in bipolar illness. In general, subjects
enrolled in studies tend to have been ill for a very long
time—15 years in bipolar trials
13—and are unstable or
unsatisfied with their current treatment.Even in studies
attempting to recruit first-episode patients, the period of
undetected or untreated illness exceeds 3 years.
14
Age itself is a common concern,with many studies having an
arbitrary age cutoff of 55 or 60 years.Even “geriatric”studies
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have been restricted, for all intents and purposes, to the
“young-old”population of patients in their sixties.Few older
patients have ever been studied,
15 despite the clear impact of
advanced age on pharmacokinetics, dynamics, and drug
metabolism
16 and on treatment response.
17 In general,the rigid
exclusions of most regulatory-oriented clinical trials have sig-
nificantly distorted the conclusions of these studies.
Public health model intervention studies
Studies that are informed by a public health model are
often called “effectiveness” studies.We avoid use of that
term since it seems to convey multiple and conflicting
meanings in different audiences.Public health studies bring
us into the world of actual practice with time-pressured
clinicians taking care of large numbers of patients with
uncertain clinical presentations,complex comorbidities,and
varying degrees of interference with ideal levels of compli-
ance.The exclusive focus on symptomatology is expanded
to include outcomes related to issues of function,disability,
morbidity, mortality, resource use, and quality of life.The
classic public health trial is used to assess the expected out-
come under usual circumstances of practice.
18
In contrast to the elegantly crafted efficacy trial, a public
health trial must be bigger in size,simpler in design,broader
in terms of inclusions and narrower in terms of exclusions,
and more representative with respect to settings of care.
These settings will not be limited to academic health centers
or tertiary care institutions, but will include primary care,
community settings, and long-term care institutions. Unlike
efficacy trials, where specially trained clinicians carry out
state-of-the-art assessment and treatment,public health tri-
als are carried out in settings of usual practice where there is
a broad and variable range of clinician expertise and experi-
ence with the disorder under study.Outcome measures will
necessarily extend beyond symptomatology to include func-
tion, disability, morbidity, mortality, health care and other
resource use,family burden,institutionalization,and quality
of life.Public health studies are not simply secondary analy-
ses of administrative data collected in large and naturalistic
databases, but are treatment trials that are broadly repre-
sentative of clinical,family,and organizational factors.
19
Types of intervention research
We begin with the assumption that the mental disorders
of late life are chronic, recurring conditions.Within this
broad perspective, three types of studies would seem to
be appropriate. First are treatment trials including both
short-term and long-term studies directed toward man-
agement of symptoms,optimization of function,and min-
imization of disability.Treatment trials of this kind are
common and well recognized in the field.The methodol-
ogy of these trials is well established and accepted by all
those involved in clinical care.However,the conceptual-
ization of the nature of treatment response is broader in
public health trials than in regulatory trials. Rather than
focusing exclusively on response as a dichotomous vari-
able, ie, responder or nonresponder, a public health
approach requires in addition that attention be paid to
speed of response, completeness of response, and dura-
bility of response.
An intervention directed at the speed of response fits
within an overall conceptualization of treatment.The
question is how can we accelerate the response to treat-
ment and how early in the treatment process can we
know when an approach to treatment is likely to fail? A
related question concerns the management of treat-
ment-resistant cases. Regardless of how treatment
response is defined,we know that invariably a subset of
patients show incomplete responses or nonresponse to
any given treatment intervention.Under the regulatory
model, the management of nonresponders and partial
responders receives relatively little attention.Yet treat-
ment-resistant patients make up a significant portion of
actual clinical practice and they account for a major
share of the mortality, morbidity, and cost of mental ill-
ness.Therefore,a public health orientation requires that
the management of treatment resistance be a priority
for investigation.
An intervention directed at the completeness of response
is considered rehabilitative.The question is how well is
well and can we improve the nature of response by tar-
geting interventions to reduce residual symptomatology
posttreatment? A rehabilitative strategy might entail aug-
mentation with a new pharmacologic or psychothera-
peutic agent or some significant alteration in lifestyles
and circumstance.
An intervention directed at durability of response is con-
sidered preventive.The question is once well, how can
we stay well and can we reduce the risk of relapse (of the
same episode) or recurrence (of a new episode) through
some longer term approaches to treatment? Interven-
tions are also preventive if they target the excessive lev-
els of disability that often characterize the mental disor-
ders of older people.As we learn more about the risk
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factors, etiology, and pathophysiology of mental disor-
ders in late life, it is conceivable that preventive inter-
ventions could be directed toward delaying the onset of
disease or even preventing the onset entirely.
20
Infrastructure considerations 
for public health model studies
In order to carry out such studies, whether they are
treatment studies, preventive interventions, or rehabili-
tative interventions, we need to identify the structural
barriers in the ways in which research is organized and
to innovate approaches to address these barriers.
Researchers and their laboratories are largely based in
academic health centers.The role of the academic health
center is being redefined in the context of health care
system reorganization,and access to patients has become
problematic. Patient-oriented research is seen as a par-
ticularly fragile enterprise at this point in time.
21,22
There are important opportunities emerging, however.
Many academic health centers are part of clinical systems
that include community hospitals, primary care and spe-
cialty care office practices, and capitated contracts.The
nonacademic settings of these large networks are where
the majority of patients are located.The new challenge
for the field is how to turn these clinical and administra-
tive networks into research networks for the develop-
ment and management of intervention trials.At the same
time, the parallel challenge is how to identify the critical
elements of academically based protocols and paradigms,
and adapt them for use in the broader community.
Advancement for academic investigators is based on
research productivity, usually measured by significant
publications and success in developing extramural fund-
ing.Large-scale,longitudinal,public-health-oriented stud-
ies typically have a very long period of time before impor-
tant publications are developed,and they usually involve
the participation of a large number of investigators.Indi-
vidual intellectual contributions can be difficult to assess
in such projects. If there is a commitment to developing
this type of research,the challenge for the field is how to
adapt promotion and tenure policies to this situation so
as to properly recognize individual contributions.
Similarly, much of the training of new investigators is
based upon a model of individual scientific activity: the
independent investigator directing a small group of junior
colleagues,fellows,students,and technicians.Training typ-
ically does not prepare investigators for participation in
large-scale endeavors. Nor are there established training
pathways into some of the newer roles in large-scale stud-
ies,database management,clinical coordination,site man-
agement,etc.
Issues in 
priority setting
Determination of priorities within this broad panorama
of intervention research is always the result of the com-
plex interaction between public health need and scien-
tific opportunity.However,this is not as straightforward
as it appears. We can estimate public health need in
many ways. Death, disability, and societal and family
burden have each been proposed as the sole criterion
for policy determination.For example,in the influential
text The Global Burden of Disease,
23 major depression,
bipolar disorder, schizophrenia, and obsessive compul-
sive disorder are all included on the list of the 10 lead-
ing causes of disability worldwide.In fact,major depres-
sion is identified as the leading cause of disability. On
the other hand, in that same study, no mental disorder
is included as a leading cause of death worldwide.
The identification of significant areas of scientific oppor-
tunity is equally problematic,with investigators from dif-
ferent fields advocating on behalf of substantial increas-
es in the investment in their particular areas of interest.
The National Advisory Mental Health Council,with the
legislative mandate to guide policy development and
program support,has become a valuable sounding board
for the identification of promising scientific opportuni-
ties.This Council has produced recent reports on genet-
ics research,
24 prevention research,
25 and the interface of
clinical trials and mental health services research.
26
Priority setting must be part of a continuing process of
programmatic adjustment,readjustment,and redirection
in the field. New treatments must be developed as our
knowledge base of basic and clinical neuroscience and
behavioral science expands. Established treatment
approaches must be fine-tuned in accordance with the
needs of patient populations and the settings in which
they receive care. Research must catch up with practice
and evaluate the many common approaches to treatment
that have developed without a firm base of research.Here
we include such approaches as continuation and mainte-
nance electroconvulsive therapy,reduction or taper strate-
gies, treatment algorithms or decision trees for patients
with treatment refractory illness,and unusual treatments
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such as methylphenidate for minor depression.A wealth
of potentially promising treatment approaches currently
exists in the form of case reports, uncontrolled studies,
letters to the editor, and Internet postings.A major goal
for the public health enterprise will be to organize and
systematically study these interventions and identify those
which are clinically valuable and those which are not.
As part of a public health mission, we must also attend
to issues of safety and consumer protection. For exam-
ple,the widespread use of over-the-counter,unregulated
treatments needs to be carefully examined for possible
benefit and for potential harm. Use of complementary
and alternative approaches is very high.
27,28 Even in
patients volunteering for participation in clinical drug
trials,use of herbal medications is substantial;in a series
of 150 such subjects,Emmanuel and colleagues
29 report
that 56% have used herbs in the last month. It is there-
fore incumbent upon us to evaluate these treatments,
including natural products such as St John’s Wort or
kava, psychophysiologic approaches such as eye move-
ment desensitization and reprocessing (EMDR), and
somatic approaches such as acupuncture,if for no other
reason than that our patients are using these in large,
uncontrolled,natural experiments.
A final priority must be dissemination.Our patients are
not helped by treatments that are available in only in sci-
entific journals.A recent example highlights the prob-
lem. Lehman and Steinwachs
30 report that fewer than
half the patients with schizophrenia in the United States
received a level of care that was consistent with the cur-
rent state of the art.This is an important finding that can-
not be ignored.As a field we must take on the challenge
of translating our research into practice and placing the
most powerful clinical tools in the hands of patients,their
families,and the clinicians that care of them.
Conclusion
The mental health field is significantly altering the cul-
ture of treatment research by moving from a narrowly
defined regulatory model to a more inclusive public
health model.This new approach to intervention promis-
es to improve patient care by addressing the types of
practical questions and functional outcomes that are typ-
ically brought to the attention of clinicians.This new gen-
eration of research is directed toward defining standards
of appropriate and cost-effective treatment for the
diverse population of patients seen in all health care set-
tings.This should not be taken to indicate that there is no
place for the highly controlled efficacy research needed
to establish that a treatment has merit. But rather it is
now the case that efficacy is the beginning of a process of
inquiry and not the end.The interdependence of chal-
lenge and opportunity, often used as a cliché, should be
considered real and entirely appropriate in this instance.
The challenge to all of us as patients,clinicians,scientists,
or educators is great.We are all having to learn to do new
things.At the same time,there is a wonderful opportuni-
ty to have a significant impact on improving patient care.
This opportunity is too good to miss.❑
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Una aproximación de salud pública a las terapias
clínicas en psiquiatría: direcciones para nuevas
investigaciones
El campo de la salud mental está transformando la
cultura de la investigación terapéutica al movili-
zarse desde un estrecho modelo regulatorio orien-
tado a la aprobación y registro de medicamentos
hacia un modelo de salud pública más inclusivo. Así
mientras los ensayos antidemencia regulados
excluirán pacientes con síntomas psiquiátricos, neu-
rológicos o con abuso de sustancias y requieren
que ellos estén físicamente sanos y que vivan con
un cuidador, es decir, el 90% de la población que
presenta Enfermedad de Alzheimer, el modelo de
salud pública promueve mejorar el cuidado del
paciente señalando los tipos de preguntas prácti-
cas y evoluciones funcionales que típicamente inte-
resan a los clínicos: ¿El tratamiento mejora la fun-
ción?  ¿Cómo podemos mantener bien a las
personas una vez que ellas se han recuperado?
¿Por qué los tratamientos no resultan efectivos en
la práctica como ocurre en los ensayos clínicos? Los
estudios de salud pública son conducidos en la
práctica mundial actual por clínicos presionados
por el tiempo, quienes cuidan de un gran número
de pacientes con cuadros clínicos poco precisos,
comorbilidades complejas y diversos grados de
interferencia con los niveles ideales de adherencia.
El foco exclusivo de síntomas se expande para
incluir evoluciones relacionadas con temas de fun-
ción, incapacidad, morbilidad, mortalidad, uso de
recursos y calidad de vida. La investigación de la
eficacia altamente controlada todavía es necesaria
para establecer el valor de un tratamiento, pero la
eficacia marca por ahora sólo el comienzo del pro-
ceso de investigación.
Une approche de Santé publique des
thérapeutiques cliniques en psychiatrie :
nouvelles voies de recherche
Le cadre conceptuel de la recherche thérapeutique
dans le domaine de la santé mentale est en train de
connaître une profonde mutation la faisant évoluer du
modèle réglementaire étroit concerné uniquement par
l’enregistrement et l'autorisation de mise sur le marché
du médicament vers un modèle de Santé publique plus
global. Ainsi, les études réglementaires classiques por-
tant sur les médicaments traitant la démence excluent
les patients présentant des symptômes psychiatriques
et neurologiques ou les toxicomanes, et exigent qu’ils
soient en bonne santé physique et qu'ils vivent avec un
soignant. Ceci a pour conséquence d'éliminer 90 % de
la population présentant une maladie d'Alzheimer. Au
contraire, le nouveau modèle de Santé publique vise à
améliorer la prise en charge des patients en donnant la
priorité aux préoccupations spécifiques des cliniciens,
qu'il s'agisse des aspects pratiques ou de ceux concer-
nant les résultats : Est-ce que le traitement facilite le
bon fonctionnement des patients ? Comment mainte-
nir les patients dans un état de bonne santé mentale
après avoir réussi à les équilibrer ? Pourquoi les traite-
ments ne sont-ils pas aussi efficaces en pratique que
lors des études cliniques ? Les études de Santé publique
sont menées dans les conditions réelles de pratique
avec des cliniciens pressés par le temps, prenant en
charge un grand nombre de patients avec des tableaux
cliniques incertains, des comorbidités complexes, et des
degrés variables d’interférences avec les niveaux d’ob-
servance idéaux. Ainsi, le centre d’intérêt autrefois diri-
gé exclusivement sur les symptômes s'est élargi pour
intégrer les notions de fonctionnement du patient, de
handicap, de morbidité, de mortalité, d'utilisation des
ressources et de qualité de vie. Si la démonstration de
la valeur du traitement passe toujours par les essais de
recherche d'efficacité hautement contrôlés, ces der-
niers ne représentent désormais que l'étape initiale du
processus d'investigation.
22. Shine KI. Some imperatives for clinical research. JAMA. 1997;278:245-246.
23. Murray CJL, Lopez AD, eds. The Global Burden of Disease. Cambridge,
Mass: Harvard University Press; 1996.
24. National Advisory Mental Health Council. Genetics and Mental Disorders.
Bethesda, Md: NIH Publication; 1998:98-4268.
25. National Advisory Mental Health Council. Priorities for Prevention Research
at NIMH. Bethesda, Md: NIH Publication; 1998:98-4321.
26. National Advisory Mental Health Council. Bridging Science and Service.
Bethesda, Md: NIH Publication; 1999:99-4353.
27. Astin JA. Why patients use alternative medicine: results of a national
study. JAMA. 1998;279:1548-1553.
28. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL.
Unconventional medicine in the United States. Prevalence, costs, and pat-
terns of use. N Engl J Med. 1993;384:246-252.
29. Emmanuel NP, Cosby C, Crawford M, et al. Prevalence of herbal product
use by subjects evaluated for pharmacological clinical trials. Poster presen-
tation, 38th Annual New Clinical Drug Evaluation Unit (NCDEU) meeting,
Boca Raton, Fla; 1998.
30. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: ini-
tial results from the Schizophrenia Patient Outcomes Research Team (PORT)
Client Survey. Schizophr Bull. 1998;24:11-20.